Latest Biomimetic Therapeutics (BMTI) Headlines
Global 3D Flat Panel TV Market 2014-2018: Several Videogame Makers Investing Heavily in Making 3D Video Games
M2 - Thu Feb 13, 6:04AM CST
Research and Markets (http://www.researchandmarkets.com/research/bjrqxw/global_3d_flat) has announced the addition of the "Global 3D Flat Panel TV Market 2014-2018" report to their offering. The analysts forecast the Global 3D Flat Panel TV market to grow at a CAGR of 15.4 percent over the period 2013-2018. One of the key factors contributing to this market growth is the increase in 3D content broadcasts. The Global 3D Flat Panel TV market has also been witnessing the emergence of 4K resolution technology. However, the health risk associated with 3D technology could pose a challenge to the growth of this market. Key vendors dominating this space are LG Electronics Inc., Samsung Electronics Co. Ltd., and Sony Corp. Other vendors mentioned in the report are Panasonic Corp., Koninklijke Philips N.V., Sharp Corp., and Toshiba Corp. Commenting on the report, an analyst from the team said: The increasing popularity of 3D gaming among consumers is driving the Global 3D Flat Panel TV market. 3D gaming is an immersive experience that provides a real world experience to its users. Several videogame makers such as Sony Computer Entertainment Inc., Nintendo Co. Ltd., Electronic Arts Inc., Capcom Co. Ltd., Take-Two Interactive Software Inc., and Warner Bros. Interactive Entertainment Inc. are investing heavily in making 3D video games. This increasing popularity of 3D games has encouraged the vendors to manufacture and upgrade 3D TVs to support 3D gaming. According to the report, 3D technology is being used in the Entertainment sector such as 3D films, video games, gaming consoles, and 3D TVs. Blockbuster movies like Avatar not only increased the public awareness of 3D media but also increased the popularity of 3D films across the world. For more information visit http://www.researchandmarkets.com/research/bj...al_3d_flat About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Analyse Trends and Forecasts in the Drug Delivery Partnering Terms and Agreements Report for 2013
M2 - Thu Jan 09, 4:49AM CST
Research and Markets (http://www.researchandmarkets.com/research/wvlwqp/drug_delivery) has announced the addition of the "Drug Delivery Partnering Terms and Agreements" report to their offering. The Drug Delivery Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the drug delivery partnering deals and agreements entered into by the worlds leading healthcare companies. This report contains over 2,600 links to online copies of actual drug delivery deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal. The initial chapters of this report provide an orientation of drug dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in drug delivery dealmaking since 2007, including details of average headline, upfront, milestone and royalty terms. Chapter 2 also contains case studies providing an insight into how companies enter into drug delivery dealmaking. Chapter 3 provides a review of the leading drug delivery deals since 2007. Deals are listed by headline value, signed by big pharma, big biotech, and most active of all biopharma companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract. Chapter 4 provides a comprehensive listing of the top 50 big pharma companies with a brief summary followed by a comprehensive listing of drug delivery deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand. Chapter 5 provides a comprehensive listing of the top 50 big biotech companies with a brief summary followed by a comprehensive listing of drug delivery deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand. Chapter 6 provides a comprehensive and detailed review of drug delivery partnering deals signed and announced since 2007, where a contract document is available in the public domain. The chapter is organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), and specific therapy focus. Each deal title links via Weblink to an online version of the deal record and the contract document, providing easy access to each contract document on demand. Chapter 7 provides a comprehensive and detailed review of drug delivery partnering deals organized by specific drug delivery technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand. Companies Mentioned: - 3M Drug Delivery Systems - 3SBio - AMAG Pharmaceuticals - Apricus Biosciences - Aradigm - BioMimetic Therapeutics - Cephalon - Cepheid - Forest Laboratories - GPC Biotech - Galapagos - Indevus Pharmaceuticals - Ipsen - Isis Pharmaceuticals - Kunwha Pharmaceuticals - Lundbeck - Lupin Pharmaceuticals - MAP Pharmaceuticals - Mylan Laboratories - Nektar Therapeutics - Novartis - SignPath Pharmaceuticals - SkyePharma - Solvay - Teva Pharmaceuticals - Uluru - Unigene Laboratories - Xi'an Zaolutang Kushidai Pharmaceuticals - Yakult Honsha - ZymoGenetics For more information visit http://www.researchandmarkets.com/research/wv...g_delivery About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Uptrend Call Working As BioMimetic Therapeutics Stock Rises 33.4% (BMTI)
Comtex SmarTrend(R) - Fri Mar 08, 9:16AM CST
SmarTrend identified an Uptrend for BioMimetic Therapeutics (NASDAQ:BMTI) on November 19th, 2012 at $7.12. In approximately 4 months, BioMimetic Therapeutics has returned 33.38% as of today's recent price of $9.49.
Wright Medical Group Inc acquires BioMimetic Therapeutics Inc for USD190m in cash and stock
M2 - Mon Mar 04, 7:11AM CST
Medical device company Wright Medical Group Inc (NasdaqGS:WMGI) revealed on Friday the completion of the acquisition of BioMimetic Therapeutics Inc for an upfront purchase price of approximately USD190m in cash and stock.
Wright Medical Group, Inc. Completes Acquisition of BioMimetic Therapeutics, Inc.
Business Wire - Fri Mar 01, 5:00AM CST
Wright Medical Group, Inc. (NASDAQ: WMGI) today announced that it has completed its acquisition of BioMimetic Therapeutics, Inc. The transaction combines BioMimetic's breakthrough biologics platform and pipeline with Wright's established sales force and product portfolio, to further accelerate growth opportunities in Wright's Extremities business.
BioMimetic Therapeutics Shares Up 33.4% Since SmarTrend's Buy Recommendation (BMTI)
Comtex SmarTrend(R) - Thu Feb 28, 4:38PM CST
SmarTrend identified an Uptrend for BioMimetic Therapeutics (NASDAQ:BMTI) on November 19th, 2012 at $7.12. In approximately 3 months, BioMimetic Therapeutics has returned 33.38% as of today's recent price of $9.49.
Shares of BMTI Up 22.7% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Thu Feb 21, 11:00AM CST
SmarTrend identified an Uptrend for BioMimetic Therapeutics (NASDAQ:BMTI) on November 19th, 2012 at $7.12. In approximately 3 months, BioMimetic Therapeutics has returned 22.70% as of today's recent price of $8.73.
Downgrade Alert for BioMimetic Therapeutics (BMTI)
Comtex SmarTrend(R) - Thu Feb 21, 6:56AM CST
BioMimetic Therapeutics (NASDAQ:BMTI) was downgraded from Buy to Neutral at Summer Street today. The stock closed yesterday at $8.77 on volume of 68,000 shares, below average daily volume of 134,000. BioMimetic Therapeutics, Inc. develops and markets drug-device products for the repair of orthopedic injuries to bond, cartilage, ligaments, and tendons. The Company combines protein therapeutics with tissue scaffolds to stimulate tissue healing and regeneration.
CMG, BMTI, MWA, PZB, PFF, VTG Are Seasonally Ripe To Go Up In the Next Five Weeks
M2 - Tue Feb 05, 6:53AM CST
BUYINS.NET / www.squeezetrigger.com is monitoring the Seasonality of Computer Modelling Group Ltd (NYSE:CMG), BioMimetic Therapeutics Inc (NASDAQ:BMTI), Mueller Water Products Inc (NYSE:MWA), Merrill Lynch Depositor Inc. PPLUS 6.7% Callable Trust Certificates Ser (NYSE
ZB), iShares S&P US Preferred Stock Index Fund (NYSE FF), Vantage Drilling Co (AMEX:VTG) and each have a high seasonal probability to go Up in the next weeks. By identifying stocks that are poised to go up or down based on seasonal tendencies, traders can increase their odds of making money. SqueezeTrigger.com is able to analyze over 20 years of data in less than 1 second for any stock in the market and determine if the stock has a long or short seasonal bias, how many trading days the move is expected to last, the probability of that move and the percentage move the stock is expected to make based on the seasonal bias. The technology used to generate these predictions is available for a low monthly fee at:
BioMimetic Therapeutics Shares Up 19.2% Since SmarTrend's Buy Recommendation (BMTI)
Comtex SmarTrend(R) - Fri Feb 01, 9:24AM CST
SmarTrend identified an Uptrend for BioMimetic Therapeutics (NASDAQ:BMTI) on November 19th, 2012 at $7.12. In approximately 2 months, BioMimetic Therapeutics has returned 19.18% as of today's recent price of $8.48.
Global Tissue Engineering and Cell Therapy Market 2011-2015 with Advanced Cell Technology Inc. and Medtronic Inc. Dominating
M2 - Wed Jan 16, 6:30AM CST
Research and Markets (http://www.researchandmarkets.com/research/2q5bhp/global_tissue) has announced the addition of the "Global Tissue Engineering and Cell Therapy Market 2011-2015" report to their offering. TechNavio's analysts forecast the Global Tissue Engineering and Cell Therapy market to grow at a CAGR of 18 percent over the period 2011-2015. One of the key factors contributing to this market growth is the significant advancements in RandD. The Global Tissue Engineering and Cell Therapy market has also been witnessing an increase in mergers and acquisitions. However, stringent regulatory requirements could pose a challenge to the growth of this market. The key vendors dominating this market space are Baxter International Inc., DePuy Inc., Medtronic Inc., Stryker Corp., and Zimmer Holdings Inc. The other vendors mentioned in the report are 3DM Inc., Aastrom Biosciences Inc., Acorda Therapeutics Inc., Advanced BioHealing Inc., Advanced Cell Technology Inc., Advanced Medical Solutions Group plc, Aeol
14.3% Return Seen to Date on SmarTrend BioMimetic Therapeutics Call (BMTI)
Comtex SmarTrend(R) - Mon Jan 14, 9:29AM CST
SmarTrend identified an Uptrend for BioMimetic Therapeutics (NASDAQ:BMTI) on November 19th, 2012 at $7.12. In approximately 2 months, BioMimetic Therapeutics has returned 14.27% as of today's recent price of $8.13.
Repligen, Pfizer Collaborate - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jan 08, 6:40PM CST
Repligen Corporation recently joined forces with Pfizer, Inc. for the advancement of its spinal muscular atrophy (SMA) program
BioMimetic's Pipeline Progresses - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jan 04, 6:46PM CST
BioMimetic announced that it has started enrolling patients for a phase II trial of its candidate, Augment
Zacks #1 Rank Additions for Thursday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jan 03, 8:14AM CST
Here are 5 stocks added to the Zacks #1 Rank ("strong buy") List for Thursday
DEF, TWC, FDL, BMTI, DHS, SATS Are Seasonally Ripe To Go Down In the Next Five Weeks
M2 - Thu Jan 03, 8:07AM CST
BUYINS.NET / www.squeezetrigger.com is monitoring the Seasonality of Guggenheim Defensive Equity ETF (NYSE
EF), Time Warner Cable Inc (NYSE:TWC), First Tr Morningstar Dividend Leaders Index Fund (NYSE:FDL), BioMimetic Therapeutics Inc (NASDAQ:BMTI), WisdomTree Equity Income Fund (NYSE HS), EchoStar Corp (NASDAQ:SATS) and each have a high seasonal probability to go Down in the next weeks. By identifying stocks that are poised to go up or down based on seasonal tendencies, traders can increase their odds of making money. SqueezeTrigger.com is able to analyze over 20 years of data in less than 1 second for any stock in the market and determine if the stock has a long or short seasonal bias, how many trading days the move is expected to last, the probability of that move and the percentage move the stock is expected to make based on the seasonal bias. The technology used to generate these predictions is available for a low monthly fee at:
BioMimetic Therapeutics, Inc. Initiates Enrollment in Augment(TM) Chronic Tendinopathy Clinical Trial
Business Wire - Thu Jan 03, 8:00AM CST
BioMimetic Therapeutics, Inc. (NASDAQ: BMTI) today announced it initiated enrollment in a Phase II clinical trial to assess the safety and efficacy of Augment(TM) Chronic Tendinopathy (ACT) as a treatment for lateral epicondylitis, commonly known as tennis elbow. The randomized, controlled trial is expected to enroll up to 100 patients at seven clinical sites in the U.S. and will evaluate the safety and therapeutic potential of escalating doses of a one-time injection of pure recombinant human platelet-derived growth factor (rhPDGF-BB) homodimer solution into the extensor carpi radialis brevis (ECRB), the tendon in the elbow that is generally the source of pain in tennis elbow. The product candidate is aimed at the large tendinosis market for which there is significant unmet clinical need with limited effective long-term treatments currently available.
Zacks #1 Rank Additions for Wednesday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Dec 19, 8:14AM CST
Here are 5 stocks added to the Zacks #1 Rank ("strong buy") List for Wednesday
Global 3D Flat Panel TV Market 2014-2018: Several Videogame Makers Investing Heavily in Making 3D Video Games
M2 - Thu Feb 13, 6:04AM CST
Research and Markets (http://www.researchandmarkets.com/research/bjrqxw/global_3d_flat) has announced the addition of the "Global 3D Flat Panel TV Market 2014-2018" report to their offering. The analysts forecast the Global 3D Flat Panel TV market to grow at a CAGR of 15.4 percent over the period 2013-2018. One of the key factors contributing to this market growth is the increase in 3D content broadcasts. The Global 3D Flat Panel TV market has also been witnessing the emergence of 4K resolution technology. However, the health risk associated with 3D technology could pose a challenge to the growth of this market. Key vendors dominating this space are LG Electronics Inc., Samsung Electronics Co. Ltd., and Sony Corp. Other vendors mentioned in the report are Panasonic Corp., Koninklijke Philips N.V., Sharp Corp., and Toshiba Corp. Commenting on the report, an analyst from the team said: The increasing popularity of 3D gaming among consumers is driving the Global 3D Flat Panel TV market. 3D gaming is an immersive experience that provides a real world experience to its users. Several videogame makers such as Sony Computer Entertainment Inc., Nintendo Co. Ltd., Electronic Arts Inc., Capcom Co. Ltd., Take-Two Interactive Software Inc., and Warner Bros. Interactive Entertainment Inc. are investing heavily in making 3D video games. This increasing popularity of 3D games has encouraged the vendors to manufacture and upgrade 3D TVs to support 3D gaming. According to the report, 3D technology is being used in the Entertainment sector such as 3D films, video games, gaming consoles, and 3D TVs. Blockbuster movies like Avatar not only increased the public awareness of 3D media but also increased the popularity of 3D films across the world. For more information visit http://www.researchandmarkets.com/research/bj...al_3d_flat About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Analyse Trends and Forecasts in the Drug Delivery Partnering Terms and Agreements Report for 2013
M2 - Thu Jan 09, 4:49AM CST
Research and Markets (http://www.researchandmarkets.com/research/wvlwqp/drug_delivery) has announced the addition of the "Drug Delivery Partnering Terms and Agreements" report to their offering. The Drug Delivery Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the drug delivery partnering deals and agreements entered into by the worlds leading healthcare companies. This report contains over 2,600 links to online copies of actual drug delivery deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal. The initial chapters of this report provide an orientation of drug dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in drug delivery dealmaking since 2007, including details of average headline, upfront, milestone and royalty terms. Chapter 2 also contains case studies providing an insight into how companies enter into drug delivery dealmaking. Chapter 3 provides a review of the leading drug delivery deals since 2007. Deals are listed by headline value, signed by big pharma, big biotech, and most active of all biopharma companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract. Chapter 4 provides a comprehensive listing of the top 50 big pharma companies with a brief summary followed by a comprehensive listing of drug delivery deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand. Chapter 5 provides a comprehensive listing of the top 50 big biotech companies with a brief summary followed by a comprehensive listing of drug delivery deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand. Chapter 6 provides a comprehensive and detailed review of drug delivery partnering deals signed and announced since 2007, where a contract document is available in the public domain. The chapter is organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), and specific therapy focus. Each deal title links via Weblink to an online version of the deal record and the contract document, providing easy access to each contract document on demand. Chapter 7 provides a comprehensive and detailed review of drug delivery partnering deals organized by specific drug delivery technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand. Companies Mentioned: - 3M Drug Delivery Systems - 3SBio - AMAG Pharmaceuticals - Apricus Biosciences - Aradigm - BioMimetic Therapeutics - Cephalon - Cepheid - Forest Laboratories - GPC Biotech - Galapagos - Indevus Pharmaceuticals - Ipsen - Isis Pharmaceuticals - Kunwha Pharmaceuticals - Lundbeck - Lupin Pharmaceuticals - MAP Pharmaceuticals - Mylan Laboratories - Nektar Therapeutics - Novartis - SignPath Pharmaceuticals - SkyePharma - Solvay - Teva Pharmaceuticals - Uluru - Unigene Laboratories - Xi'an Zaolutang Kushidai Pharmaceuticals - Yakult Honsha - ZymoGenetics For more information visit http://www.researchandmarkets.com/research/wv...g_delivery About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Uptrend Call Working As BioMimetic Therapeutics Stock Rises 33.4% (BMTI)
Comtex SmarTrend(R) - Fri Mar 08, 9:16AM CST
SmarTrend identified an Uptrend for BioMimetic Therapeutics (NASDAQ:BMTI) on November 19th, 2012 at $7.12. In approximately 4 months, BioMimetic Therapeutics has returned 33.38% as of today's recent price of $9.49.
Wright Medical Group Inc acquires BioMimetic Therapeutics Inc for USD190m in cash and stock
M2 - Mon Mar 04, 7:11AM CST
Medical device company Wright Medical Group Inc (NasdaqGS:WMGI) revealed on Friday the completion of the acquisition of BioMimetic Therapeutics Inc for an upfront purchase price of approximately USD190m in cash and stock.
Wright Medical Group, Inc. Completes Acquisition of BioMimetic Therapeutics, Inc.
Business Wire - Fri Mar 01, 5:00AM CST
Wright Medical Group, Inc. (NASDAQ: WMGI) today announced that it has completed its acquisition of BioMimetic Therapeutics, Inc. The transaction combines BioMimetic's breakthrough biologics platform and pipeline with Wright's established sales force and product portfolio, to further accelerate growth opportunities in Wright's Extremities business.
BioMimetic Therapeutics Shares Up 33.4% Since SmarTrend's Buy Recommendation (BMTI)
Comtex SmarTrend(R) - Thu Feb 28, 4:38PM CST
SmarTrend identified an Uptrend for BioMimetic Therapeutics (NASDAQ:BMTI) on November 19th, 2012 at $7.12. In approximately 3 months, BioMimetic Therapeutics has returned 33.38% as of today's recent price of $9.49.
Shares of BMTI Up 22.7% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Thu Feb 21, 11:00AM CST
SmarTrend identified an Uptrend for BioMimetic Therapeutics (NASDAQ:BMTI) on November 19th, 2012 at $7.12. In approximately 3 months, BioMimetic Therapeutics has returned 22.70% as of today's recent price of $8.73.
Downgrade Alert for BioMimetic Therapeutics (BMTI)
Comtex SmarTrend(R) - Thu Feb 21, 6:56AM CST
BioMimetic Therapeutics (NASDAQ:BMTI) was downgraded from Buy to Neutral at Summer Street today. The stock closed yesterday at $8.77 on volume of 68,000 shares, below average daily volume of 134,000. BioMimetic Therapeutics, Inc. develops and markets drug-device products for the repair of orthopedic injuries to bond, cartilage, ligaments, and tendons. The Company combines protein therapeutics with tissue scaffolds to stimulate tissue healing and regeneration.
CMG, BMTI, MWA, PZB, PFF, VTG Are Seasonally Ripe To Go Up In the Next Five Weeks
M2 - Tue Feb 05, 6:53AM CST
BUYINS.NET / www.squeezetrigger.com is monitoring the Seasonality of Computer Modelling Group Ltd (NYSE:CMG), BioMimetic Therapeutics Inc (NASDAQ:BMTI), Mueller Water Products Inc (NYSE:MWA), Merrill Lynch Depositor Inc. PPLUS 6.7% Callable Trust Certificates Ser (NYSE
ZB), iShares S&P US Preferred Stock Index Fund (NYSE FF), Vantage Drilling Co (AMEX:VTG) and each have a high seasonal probability to go Up in the next weeks. By identifying stocks that are poised to go up or down based on seasonal tendencies, traders can increase their odds of making money. SqueezeTrigger.com is able to analyze over 20 years of data in less than 1 second for any stock in the market and determine if the stock has a long or short seasonal bias, how many trading days the move is expected to last, the probability of that move and the percentage move the stock is expected to make based on the seasonal bias. The technology used to generate these predictions is available for a low monthly fee at: BioMimetic Therapeutics Shares Up 19.2% Since SmarTrend's Buy Recommendation (BMTI)
Comtex SmarTrend(R) - Fri Feb 01, 9:24AM CST
SmarTrend identified an Uptrend for BioMimetic Therapeutics (NASDAQ:BMTI) on November 19th, 2012 at $7.12. In approximately 2 months, BioMimetic Therapeutics has returned 19.18% as of today's recent price of $8.48.
Global Tissue Engineering and Cell Therapy Market 2011-2015 with Advanced Cell Technology Inc. and Medtronic Inc. Dominating
M2 - Wed Jan 16, 6:30AM CST
Research and Markets (http://www.researchandmarkets.com/research/2q5bhp/global_tissue) has announced the addition of the "Global Tissue Engineering and Cell Therapy Market 2011-2015" report to their offering. TechNavio's analysts forecast the Global Tissue Engineering and Cell Therapy market to grow at a CAGR of 18 percent over the period 2011-2015. One of the key factors contributing to this market growth is the significant advancements in RandD. The Global Tissue Engineering and Cell Therapy market has also been witnessing an increase in mergers and acquisitions. However, stringent regulatory requirements could pose a challenge to the growth of this market. The key vendors dominating this market space are Baxter International Inc., DePuy Inc., Medtronic Inc., Stryker Corp., and Zimmer Holdings Inc. The other vendors mentioned in the report are 3DM Inc., Aastrom Biosciences Inc., Acorda Therapeutics Inc., Advanced BioHealing Inc., Advanced Cell Technology Inc., Advanced Medical Solutions Group plc, Aeol
14.3% Return Seen to Date on SmarTrend BioMimetic Therapeutics Call (BMTI)
Comtex SmarTrend(R) - Mon Jan 14, 9:29AM CST
SmarTrend identified an Uptrend for BioMimetic Therapeutics (NASDAQ:BMTI) on November 19th, 2012 at $7.12. In approximately 2 months, BioMimetic Therapeutics has returned 14.27% as of today's recent price of $8.13.
Repligen, Pfizer Collaborate - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jan 08, 6:40PM CST
Repligen Corporation recently joined forces with Pfizer, Inc. for the advancement of its spinal muscular atrophy (SMA) program
BioMimetic's Pipeline Progresses - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jan 04, 6:46PM CST
BioMimetic announced that it has started enrolling patients for a phase II trial of its candidate, Augment
Zacks #1 Rank Additions for Thursday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jan 03, 8:14AM CST
Here are 5 stocks added to the Zacks #1 Rank ("strong buy") List for Thursday
DEF, TWC, FDL, BMTI, DHS, SATS Are Seasonally Ripe To Go Down In the Next Five Weeks
M2 - Thu Jan 03, 8:07AM CST
BUYINS.NET / www.squeezetrigger.com is monitoring the Seasonality of Guggenheim Defensive Equity ETF (NYSE
EF), Time Warner Cable Inc (NYSE:TWC), First Tr Morningstar Dividend Leaders Index Fund (NYSE:FDL), BioMimetic Therapeutics Inc (NASDAQ:BMTI), WisdomTree Equity Income Fund (NYSE HS), EchoStar Corp (NASDAQ:SATS) and each have a high seasonal probability to go Down in the next weeks. By identifying stocks that are poised to go up or down based on seasonal tendencies, traders can increase their odds of making money. SqueezeTrigger.com is able to analyze over 20 years of data in less than 1 second for any stock in the market and determine if the stock has a long or short seasonal bias, how many trading days the move is expected to last, the probability of that move and the percentage move the stock is expected to make based on the seasonal bias. The technology used to generate these predictions is available for a low monthly fee at: BioMimetic Therapeutics, Inc. Initiates Enrollment in Augment(TM) Chronic Tendinopathy Clinical Trial
Business Wire - Thu Jan 03, 8:00AM CST
BioMimetic Therapeutics, Inc. (NASDAQ: BMTI) today announced it initiated enrollment in a Phase II clinical trial to assess the safety and efficacy of Augment(TM) Chronic Tendinopathy (ACT) as a treatment for lateral epicondylitis, commonly known as tennis elbow. The randomized, controlled trial is expected to enroll up to 100 patients at seven clinical sites in the U.S. and will evaluate the safety and therapeutic potential of escalating doses of a one-time injection of pure recombinant human platelet-derived growth factor (rhPDGF-BB) homodimer solution into the extensor carpi radialis brevis (ECRB), the tendon in the elbow that is generally the source of pain in tennis elbow. The product candidate is aimed at the large tendinosis market for which there is significant unmet clinical need with limited effective long-term treatments currently available.
Zacks #1 Rank Additions for Wednesday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Dec 19, 8:14AM CST
Here are 5 stocks added to the Zacks #1 Rank ("strong buy") List for Wednesday
